查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1867492

PD-L1 和 PIK3CA 检测：全球市场份额和排名、总收入和需求预测（2025-2031 年）

PD-L1 and PIK3CA Testing - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 92 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

全球 PD-L1 和 PIK3CA 检测市场预计在 2024 年达到 8.7 亿美元，预计到 2031 年将达到 26.5 亿美元，在预测期（2025-2031 年）以 16.9% 的复合年增长率成长。

PD-L1生物标记检测测量癌细胞上PD-L1的含量。 PD-L1是一种蛋白质，它能阻止免疫细胞攻击体内无害细胞。正常情况下，免疫系统会攻击病毒和细菌等外来物质，而不会攻击自身健康的细胞。一些癌细胞具有高水平的PD-L1，这使它们能够「欺骗」免疫系统，避免被当作外来物攻击。目前的PD-L1检测是基于免疫组织化学（IHC）技术，该技术利用抗体检测组织切片（例如肝臟、胰臟、心臟等）中细胞表面存在的蛋白质（抗原）。 PD-L1是一种配体，它与PD-1（程序性死亡受体1）结合，PD-1表达于活化的T细胞上，并在肿瘤细胞逃避免疫反应中发挥作用。 PD-L1抑制T细胞的活化和增殖，因此作为癌症治疗的重要标靶而备受关注。免疫组化（IHC）检测PD-L1蛋白被广泛用作抗PD-1/PD-L1疗法的预测性生物标记检测。 PIK3CA基因编码一种脂质激酶，参与多种讯息传递路径。这些通路影响细胞增生、凋亡和生长等功能。 PIK3CA突变会活化PI3K-PTEN-AKT通路，该通路位于EGFR和RAS-RAF-MAPK通路的下游。 PIK3CA突变可导致致癌性，且此过程独立于RAS或RAF突变。 PIK3CA突变在约15%至30%的乳癌、子宫内膜癌和大肠癌中发现，在肺癌和其他癌症类型中发生率较低。 PIK3CA突变与乳癌、子宫内膜癌和大肠直肠癌患者预后不良和对特定治疗反应不佳有关。

全球PD-L1和PIK3CA检测市场正经历强劲增长，这主要得益于精准肿瘤学的日益普及以及标靶治疗在包括非小细胞肺癌（NSCLC）、乳癌和子宫颈癌在内的多种癌症类型中的核准。伴随诊断（CDx）与免疫疗法和PI3K抑制剂联合应用的需求不断增长，加速了PD-L1免疫组化（IHC）和PIK3CA突变检测的普及。此外，政府主导的癌症筛检政策、次世代定序（NGS）平台的进步以及生物标记在临床决策中日益广泛的应用，也推动了临床对这些检测的依赖性增强。大型製药公司也在大力投资需要基于生物标记进行患者分层的临床试验，进一步推动了市场渗透。

儘管PD-L1和PIK3CA检测市场呈现成长态势，但仍面临许多挑战。检测结果解读的差异、检测方法缺乏标准化以及肿瘤异质性的复杂性，常常导致临床结果不一致，并削弱人们对检测结果的信心。伴随诊断方面的监管障碍（尤其是在新兴市场）以及基于次世代定序（NGS）平台的高成本，都阻碍了其普及应用。此外，健保报销的不确定性以及医疗基础设施的差异，限制了中低收入地区获得检测服务的机会。癌症诊断领域的不断演变也对该市场产生影响，新型生物标记和多基因检测组合的出现，可能会使临床关注点从PD-L1和PIK3CA等单一分析物检测转移开来。

本报告旨在按地区/国家、类型和应用对全球 PD-L1 和 PIK3CA 检测市场进行全面分析，重点关注总收入、市场份额和主要企业的排名。

PD-L1 和 PIK3CA 检测市场规模、估算和预测均以销售收入为指标，以 2024 年为基准年，并包含 2020 年至 2031 年的历史资料和预测资料。定量和定性分析将帮助读者制定 PD-L1 和 PIK3CA 检测的业务和成长策略，评估市场竞争，分析自身在当前市场中的地位，并做出明智的商业决策。

市场区隔

公司

  • Agilent Technologies
  • Roche
  • QIAGEN
  • EntroGen
  • Amoy Diagnostics
  • ACCB Biotech

按类型分類的细分市场

  • PD-L1检测
  • PIK3CA 检测

应用领域

  • 医院
  • 诊断中心
  • 其他的

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for PD-L1 and PIK3CA Testing was estimated to be worth US$ 870 million in 2024 and is forecast to a readjusted size of US$ 2650 million by 2031 with a CAGR of 16.9% during the forecast period 2025-2031.

PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances. Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart). PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti-PD-1/PD-L1 therapies. PIK3CA is a gene that encodes a lipid kinase involved in multiple signaling pathways. These pathways influence cellular functions such as growth, death, and proliferation. PIK3CA mutations activate the PI3K-PTEN-AKT pathway, which is downstream from both the EGFR and the RAS-RAF-MAPK pathways. PIK3CA mutations may cause oncogenic transformation independent of RAS or RAF mutations. PIK3CA mutations occur in about 15% to 30% of breast, endometrial, and colon cancers. They occur less frequently in lung cancer and other types of cancer. Presence of PIK3CA mutations is associated with poor prognosis and lack of response to specific therapies in patients with breast, endometrial, or colon cancer.

The global PD-L1 and PIK3CA testing market is experiencing robust growth, driven by the expanding use of precision oncology and the approval of targeted therapies across various cancer types, including NSCLC, breast, and cervical cancers. The increasing demand for companion diagnostics (CDx) in tandem with immunotherapies and PI3K inhibitors is accelerating the adoption of PD-L1 IHC assays and PIK3CA mutation tests. Additionally, government-backed initiatives for cancer screening, advancements in next-generation sequencing (NGS) platforms, and the growing integration of biomarkers into clinical decision-making are fostering greater clinical reliance on these tests. Leading pharmaceutical companies are also investing heavily in clinical trials that necessitate biomarker-based patient stratification, further boosting market penetration.

Despite the growth, the PD-L1 and PIK3CA testing market faces several challenges. Variability in test interpretation, lack of assay standardization, and the complexity of tumor heterogeneity often lead to inconsistent clinical outcomes, hampering trust in testing results. Regulatory hurdles for companion diagnostics, especially in emerging markets, and the high cost of NGS-based platforms pose barriers to adoption. Moreover, reimbursement uncertainty and disparities in healthcare infrastructure limit access in low-to-middle-income regions. The market is also affected by the evolving landscape of oncology diagnostics, where novel biomarkers and multi-gene panels may shift clinical focus away from single-analyte tests like PD-L1 or PIK3CA.

This report aims to provide a comprehensive presentation of the global market for PD-L1 and PIK3CA Testing, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of PD-L1 and PIK3CA Testing by region & country, by Type, and by Application.

The PD-L1 and PIK3CA Testing market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PD-L1 and PIK3CA Testing.

Market Segmentation

By Company

  • Agilent Technologies
  • Roche
  • QIAGEN
  • EntroGen
  • Amoy Diagnostics
  • ACCB Biotech

Segment by Type

  • PD-L1 Testing
  • PIK3CA Testing

Segment by Application

  • Hospital
  • Diagnostic Center
  • Others

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of PD-L1 and PIK3CA Testing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of PD-L1 and PIK3CA Testing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of PD-L1 and PIK3CA Testing in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 PD-L1 and PIK3CA Testing Product Introduction
  • 1.2 Global PD-L1 and PIK3CA Testing Market Size Forecast (2020-2031)
  • 1.3 PD-L1 and PIK3CA Testing Market Trends & Drivers
    • 1.3.1 PD-L1 and PIK3CA Testing Industry Trends
    • 1.3.2 PD-L1 and PIK3CA Testing Market Drivers & Opportunity
    • 1.3.3 PD-L1 and PIK3CA Testing Market Challenges
    • 1.3.4 PD-L1 and PIK3CA Testing Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global PD-L1 and PIK3CA Testing Players Revenue Ranking (2024)
  • 2.2 Global PD-L1 and PIK3CA Testing Revenue by Company (2020-2025)
  • 2.3 Key Companies PD-L1 and PIK3CA Testing Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies PD-L1 and PIK3CA Testing Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of PD-L1 and PIK3CA Testing
  • 2.6 PD-L1 and PIK3CA Testing Market Competitive Analysis
    • 2.6.1 PD-L1 and PIK3CA Testing Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by PD-L1 and PIK3CA Testing Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PD-L1 and PIK3CA Testing as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 PD-L1 Testing
    • 3.1.2 PIK3CA Testing
  • 3.2 Global PD-L1 and PIK3CA Testing Sales Value by Type
    • 3.2.1 Global PD-L1 and PIK3CA Testing Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global PD-L1 and PIK3CA Testing Sales Value, by Type (2020-2031)
    • 3.2.3 Global PD-L1 and PIK3CA Testing Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Hospital
    • 4.1.2 Diagnostic Center
    • 4.1.3 Others
  • 4.2 Global PD-L1 and PIK3CA Testing Sales Value by Application
    • 4.2.1 Global PD-L1 and PIK3CA Testing Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global PD-L1 and PIK3CA Testing Sales Value, by Application (2020-2031)
    • 4.2.3 Global PD-L1 and PIK3CA Testing Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global PD-L1 and PIK3CA Testing Sales Value by Region
    • 5.1.1 Global PD-L1 and PIK3CA Testing Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global PD-L1 and PIK3CA Testing Sales Value by Region (2020-2025)
    • 5.1.3 Global PD-L1 and PIK3CA Testing Sales Value by Region (2026-2031)
    • 5.1.4 Global PD-L1 and PIK3CA Testing Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America PD-L1 and PIK3CA Testing Sales Value, 2020-2031
    • 5.2.2 North America PD-L1 and PIK3CA Testing Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe PD-L1 and PIK3CA Testing Sales Value, 2020-2031
    • 5.3.2 Europe PD-L1 and PIK3CA Testing Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific PD-L1 and PIK3CA Testing Sales Value, 2020-2031
    • 5.4.2 Asia Pacific PD-L1 and PIK3CA Testing Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America PD-L1 and PIK3CA Testing Sales Value, 2020-2031
    • 5.5.2 South America PD-L1 and PIK3CA Testing Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa PD-L1 and PIK3CA Testing Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa PD-L1 and PIK3CA Testing Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions PD-L1 and PIK3CA Testing Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions PD-L1 and PIK3CA Testing Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States PD-L1 and PIK3CA Testing Sales Value, 2020-2031
    • 6.3.2 United States PD-L1 and PIK3CA Testing Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States PD-L1 and PIK3CA Testing Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe PD-L1 and PIK3CA Testing Sales Value, 2020-2031
    • 6.4.2 Europe PD-L1 and PIK3CA Testing Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe PD-L1 and PIK3CA Testing Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China PD-L1 and PIK3CA Testing Sales Value, 2020-2031
    • 6.5.2 China PD-L1 and PIK3CA Testing Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China PD-L1 and PIK3CA Testing Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan PD-L1 and PIK3CA Testing Sales Value, 2020-2031
    • 6.6.2 Japan PD-L1 and PIK3CA Testing Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan PD-L1 and PIK3CA Testing Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea PD-L1 and PIK3CA Testing Sales Value, 2020-2031
    • 6.7.2 South Korea PD-L1 and PIK3CA Testing Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea PD-L1 and PIK3CA Testing Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia PD-L1 and PIK3CA Testing Sales Value, 2020-2031
    • 6.8.2 Southeast Asia PD-L1 and PIK3CA Testing Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia PD-L1 and PIK3CA Testing Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India PD-L1 and PIK3CA Testing Sales Value, 2020-2031
    • 6.9.2 India PD-L1 and PIK3CA Testing Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India PD-L1 and PIK3CA Testing Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Agilent Technologies
    • 7.1.1 Agilent Technologies Profile
    • 7.1.2 Agilent Technologies Main Business
    • 7.1.3 Agilent Technologies PD-L1 and PIK3CA Testing Products, Services and Solutions
    • 7.1.4 Agilent Technologies PD-L1 and PIK3CA Testing Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Agilent Technologies Recent Developments
  • 7.2 Roche
    • 7.2.1 Roche Profile
    • 7.2.2 Roche Main Business
    • 7.2.3 Roche PD-L1 and PIK3CA Testing Products, Services and Solutions
    • 7.2.4 Roche PD-L1 and PIK3CA Testing Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Roche Recent Developments
  • 7.3 QIAGEN
    • 7.3.1 QIAGEN Profile
    • 7.3.2 QIAGEN Main Business
    • 7.3.3 QIAGEN PD-L1 and PIK3CA Testing Products, Services and Solutions
    • 7.3.4 QIAGEN PD-L1 and PIK3CA Testing Revenue (US$ Million) & (2020-2025)
    • 7.3.5 QIAGEN Recent Developments
  • 7.4 EntroGen
    • 7.4.1 EntroGen Profile
    • 7.4.2 EntroGen Main Business
    • 7.4.3 EntroGen PD-L1 and PIK3CA Testing Products, Services and Solutions
    • 7.4.4 EntroGen PD-L1 and PIK3CA Testing Revenue (US$ Million) & (2020-2025)
    • 7.4.5 EntroGen Recent Developments
  • 7.5 Amoy Diagnostics
    • 7.5.1 Amoy Diagnostics Profile
    • 7.5.2 Amoy Diagnostics Main Business
    • 7.5.3 Amoy Diagnostics PD-L1 and PIK3CA Testing Products, Services and Solutions
    • 7.5.4 Amoy Diagnostics PD-L1 and PIK3CA Testing Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Amoy Diagnostics Recent Developments
  • 7.6 ACCB Biotech
    • 7.6.1 ACCB Biotech Profile
    • 7.6.2 ACCB Biotech Main Business
    • 7.6.3 ACCB Biotech PD-L1 and PIK3CA Testing Products, Services and Solutions
    • 7.6.4 ACCB Biotech PD-L1 and PIK3CA Testing Revenue (US$ Million) & (2020-2025)
    • 7.6.5 ACCB Biotech Recent Developments

8 Industry Chain Analysis

  • 8.1 PD-L1 and PIK3CA Testing Industrial Chain
  • 8.2 PD-L1 and PIK3CA Testing Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 PD-L1 and PIK3CA Testing Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 PD-L1 and PIK3CA Testing Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. PD-L1 and PIK3CA Testing Market Trends
  • Table 2. PD-L1 and PIK3CA Testing Market Drivers & Opportunity
  • Table 3. PD-L1 and PIK3CA Testing Market Challenges
  • Table 4. PD-L1 and PIK3CA Testing Market Restraints
  • Table 5. Global PD-L1 and PIK3CA Testing Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global PD-L1 and PIK3CA Testing Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies PD-L1 and PIK3CA Testing Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies PD-L1 and PIK3CA Testing Product Type
  • Table 9. Key Companies Time to Begin Mass Production of PD-L1 and PIK3CA Testing
  • Table 10. Global PD-L1 and PIK3CA Testing Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PD-L1 and PIK3CA Testing as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global PD-L1 and PIK3CA Testing Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global PD-L1 and PIK3CA Testing Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global PD-L1 and PIK3CA Testing Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global PD-L1 and PIK3CA Testing Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global PD-L1 and PIK3CA Testing Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global PD-L1 and PIK3CA Testing Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global PD-L1 and PIK3CA Testing Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global PD-L1 and PIK3CA Testing Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global PD-L1 and PIK3CA Testing Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global PD-L1 and PIK3CA Testing Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global PD-L1 and PIK3CA Testing Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global PD-L1 and PIK3CA Testing Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global PD-L1 and PIK3CA Testing Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global PD-L1 and PIK3CA Testing Sales Value by Region (2020-2025) & (%)
  • Table 27. Global PD-L1 and PIK3CA Testing Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions PD-L1 and PIK3CA Testing Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions PD-L1 and PIK3CA Testing Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions PD-L1 and PIK3CA Testing Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Agilent Technologies Basic Information List
  • Table 32. Agilent Technologies Description and Business Overview
  • Table 33. Agilent Technologies PD-L1 and PIK3CA Testing Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in PD-L1 and PIK3CA Testing Business of Agilent Technologies (2020-2025)
  • Table 35. Agilent Technologies Recent Developments
  • Table 36. Roche Basic Information List
  • Table 37. Roche Description and Business Overview
  • Table 38. Roche PD-L1 and PIK3CA Testing Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in PD-L1 and PIK3CA Testing Business of Roche (2020-2025)
  • Table 40. Roche Recent Developments
  • Table 41. QIAGEN Basic Information List
  • Table 42. QIAGEN Description and Business Overview
  • Table 43. QIAGEN PD-L1 and PIK3CA Testing Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in PD-L1 and PIK3CA Testing Business of QIAGEN (2020-2025)
  • Table 45. QIAGEN Recent Developments
  • Table 46. EntroGen Basic Information List
  • Table 47. EntroGen Description and Business Overview
  • Table 48. EntroGen PD-L1 and PIK3CA Testing Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in PD-L1 and PIK3CA Testing Business of EntroGen (2020-2025)
  • Table 50. EntroGen Recent Developments
  • Table 51. Amoy Diagnostics Basic Information List
  • Table 52. Amoy Diagnostics Description and Business Overview
  • Table 53. Amoy Diagnostics PD-L1 and PIK3CA Testing Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in PD-L1 and PIK3CA Testing Business of Amoy Diagnostics (2020-2025)
  • Table 55. Amoy Diagnostics Recent Developments
  • Table 56. ACCB Biotech Basic Information List
  • Table 57. ACCB Biotech Description and Business Overview
  • Table 58. ACCB Biotech PD-L1 and PIK3CA Testing Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in PD-L1 and PIK3CA Testing Business of ACCB Biotech (2020-2025)
  • Table 60. ACCB Biotech Recent Developments
  • Table 61. Key Raw Materials Lists
  • Table 62. Raw Materials Key Suppliers Lists
  • Table 63. PD-L1 and PIK3CA Testing Downstream Customers
  • Table 64. PD-L1 and PIK3CA Testing Distributors List
  • Table 65. Research Programs/Design for This Report
  • Table 66. Key Data Information from Secondary Sources
  • Table 67. Key Data Information from Primary Sources

List of Figures

  • Figure 1. PD-L1 and PIK3CA Testing Product Picture
  • Figure 2. Global PD-L1 and PIK3CA Testing Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global PD-L1 and PIK3CA Testing Sales Value (2020-2031) & (US$ Million)
  • Figure 4. PD-L1 and PIK3CA Testing Report Years Considered
  • Figure 5. Global PD-L1 and PIK3CA Testing Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by PD-L1 and PIK3CA Testing Revenue in 2024
  • Figure 7. PD-L1 and PIK3CA Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. PD-L1 Testing Picture
  • Figure 9. PIK3CA Testing Picture
  • Figure 10. Global PD-L1 and PIK3CA Testing Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 11. Global PD-L1 and PIK3CA Testing Sales Value Market Share by Type, 2024 & 2031
  • Figure 12. Product Picture of Hospital
  • Figure 13. Product Picture of Diagnostic Center
  • Figure 14. Product Picture of Others
  • Figure 15. Global PD-L1 and PIK3CA Testing Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 16. Global PD-L1 and PIK3CA Testing Sales Value Market Share by Application, 2024 & 2031
  • Figure 17. North America PD-L1 and PIK3CA Testing Sales Value (2020-2031) & (US$ Million)
  • Figure 18. North America PD-L1 and PIK3CA Testing Sales Value by Country (%), 2024 VS 2031
  • Figure 19. Europe PD-L1 and PIK3CA Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 20. Europe PD-L1 and PIK3CA Testing Sales Value by Country (%), 2024 VS 2031
  • Figure 21. Asia Pacific PD-L1 and PIK3CA Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 22. Asia Pacific PD-L1 and PIK3CA Testing Sales Value by Region (%), 2024 VS 2031
  • Figure 23. South America PD-L1 and PIK3CA Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 24. South America PD-L1 and PIK3CA Testing Sales Value by Country (%), 2024 VS 2031
  • Figure 25. Middle East & Africa PD-L1 and PIK3CA Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 26. Middle East & Africa PD-L1 and PIK3CA Testing Sales Value by Country (%), 2024 VS 2031
  • Figure 27. Key Countries/Regions PD-L1 and PIK3CA Testing Sales Value (%), (2020-2031)
  • Figure 28. United States PD-L1 and PIK3CA Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 29. United States PD-L1 and PIK3CA Testing Sales Value by Type (%), 2024 VS 2031
  • Figure 30. United States PD-L1 and PIK3CA Testing Sales Value by Application (%), 2024 VS 2031
  • Figure 31. Europe PD-L1 and PIK3CA Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 32. Europe PD-L1 and PIK3CA Testing Sales Value by Type (%), 2024 VS 2031
  • Figure 33. Europe PD-L1 and PIK3CA Testing Sales Value by Application (%), 2024 VS 2031
  • Figure 34. China PD-L1 and PIK3CA Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 35. China PD-L1 and PIK3CA Testing Sales Value by Type (%), 2024 VS 2031
  • Figure 36. China PD-L1 and PIK3CA Testing Sales Value by Application (%), 2024 VS 2031
  • Figure 37. Japan PD-L1 and PIK3CA Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 38. Japan PD-L1 and PIK3CA Testing Sales Value by Type (%), 2024 VS 2031
  • Figure 39. Japan PD-L1 and PIK3CA Testing Sales Value by Application (%), 2024 VS 2031
  • Figure 40. South Korea PD-L1 and PIK3CA Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 41. South Korea PD-L1 and PIK3CA Testing Sales Value by Type (%), 2024 VS 2031
  • Figure 42. South Korea PD-L1 and PIK3CA Testing Sales Value by Application (%), 2024 VS 2031
  • Figure 43. Southeast Asia PD-L1 and PIK3CA Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 44. Southeast Asia PD-L1 and PIK3CA Testing Sales Value by Type (%), 2024 VS 2031
  • Figure 45. Southeast Asia PD-L1 and PIK3CA Testing Sales Value by Application (%), 2024 VS 2031
  • Figure 46. India PD-L1 and PIK3CA Testing Sales Value, (2020-2031) & (US$ Million)
  • Figure 47. India PD-L1 and PIK3CA Testing Sales Value by Type (%), 2024 VS 2031
  • Figure 48. India PD-L1 and PIK3CA Testing Sales Value by Application (%), 2024 VS 2031
  • Figure 49. PD-L1 and PIK3CA Testing Industrial Chain
  • Figure 50. PD-L1 and PIK3CA Testing Manufacturing Cost Structure
  • Figure 51. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 52. Bottom-up and Top-down Approaches for This Report
  • Figure 53. Data Triangulation
  • Figure 54. Key Executives Interviewed